Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Exercise and Motor Learning After Stroke
Feedback and Cognition During Locomotor Learning Post Stroke
Status: Enrolling
Updated:  12/31/1969
University of Delaware
mi
from
Newark, DE
Exercise and Motor Learning After Stroke
Feedback and Cognition During Locomotor Learning Post Stroke
Status: Enrolling
Updated: 12/31/1969
University of Delaware
mi
from
Newark, DE
Click here to add this to my saved trials
Maximizing Independence at Home (MIND at Home)
Maximizing Independence at Home (MIND at Home): Dementia Care at Home Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Maximizing Independence at Home (MIND at Home)
Maximizing Independence at Home (MIND at Home): Dementia Care at Home Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MISTWAVE)
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MIST WAVE)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MISTWAVE)
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MIST WAVE)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MISTWAVE)
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MIST WAVE)
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MISTWAVE)
Mild Acute Ischemic Stroke With Large Vessel Occlusion (MIST WAVE)
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Anaheim, CA
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
San Diego, CA
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Hialeah, FL
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Chicago, IL
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Naperville, IL
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Naperville, IL
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Lincoln, NE
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Houston, TX
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Houston, TX
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Gulf Breeze, FL
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Dallas, TX
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
San Juan,
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
San Juan,
Click here to add this to my saved trials
NMDA Receptors in Motor Learning in Humans
NMDA Receptors in Motor Learning in Humans
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
NMDA Receptors in Motor Learning in Humans
NMDA Receptors in Motor Learning in Humans
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Genetic Evaluation for Medication Selection (GEMS) Study
Pharmacogenic Guidance to Optimize Safety and Efficacy of Psychotropic Drug Use in Treatment of Behavioral and Psychiatric Symptoms in Dementia
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Genetic Evaluation for Medication Selection (GEMS) Study
Pharmacogenic Guidance to Optimize Safety and Efficacy of Psychotropic Drug Use in Treatment of Behavioral and Psychiatric Symptoms in Dementia
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
A Method Development Clinical Study Investigating the Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Wayne, IN
A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
A Method Development Clinical Study Investigating the Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Naples, FL
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Northbrook, IL
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Biddeford, ME
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Biddeford, ME
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toms River, NJ
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Schenectady, NY
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Schenectady, NY
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Akron, OH
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Green, OH
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Green, OH
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greensburg, PA
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greensburg, PA
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Franklin, TN
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Franklin, TN
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Round Rock, TX
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newport News, VA
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Roanoke, VA
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
mi
from
Sofia,
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
mi
from
Sofia,
Click here to add this to my saved trials
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Phoenix, AZ
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Little Rock, AR
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Los Angeles, CA
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials